Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on eye care and expanding into adjacent therapeutic areas. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), is a prescription eye drop for the treatment of Demodex blepharitis, targeting the root cause of the disease — Demodex mite infestation. Beyond XDEMVY, Tarsus is developing a pipeline that includes TP-04 (a lotilaner-based gel for ocular rosacea, Phase 2), TP-05 (an oral lotilaner formulation for Lyme disease prevention, Phase 2), IRX-101 (an investigational ocular antiseptic for intravitreal injection procedures, acquired via iRenix Medical), and gildeuretinol acetate/ALK-001 (an oral therapy for Stargardt disease, Phase 3, via pending Alkeus Pharmaceuticals acquisition). The company has established a growing commercial infrastructure with direct-to-consumer marketing campaigns and an expanding sales force targeting eye care professionals across the United States. Tarsus also has a China out-license partnership for its lotilaner-based products. The company trades on NASDAQ under the ticker TARS. Updated Aug 6, 2026